Lyell Immunopharma
LYEL
LYEL
79 hedge funds and large institutions have $503M invested in Lyell Immunopharma in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 36 increasing their positions, 10 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
0.29% more ownership
Funds ownership: 1.78% → 2.07% (+0.29%)
24% less capital invested
Capital invested by funds: $662M → $503M (-$159M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Holders
79
Holding in Top 10
3
Calls
$3.05M
Puts
$92K
Top Buyers
| 1 | +$33.5M | |
| 2 | +$29.3M | |
| 3 | +$7.43M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.17M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.52M |
Top Sellers
| 1 | -$27.1M | |
| 2 | -$7.8M | |
| 3 | -$4.18M | |
| 4 |
Morgan Stanley
New York
|
-$3.25M |
| 5 |
HF
HRT Financial
New York
|
-$1.72M |